Intermittent Schedules of the Oral RAF/MEK Inhibitor CH5126766/Avutometinib in Patients With RAS/RAF-Mutant Solid Tumours and Multiple Myeloma: a Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study
Intermittent Schedules of the Oral RAF/MEK Inhibitor CH5126766/Avutometinib in Patients With RAS/RAF-Mutant Solid Tumours and Multiple Myeloma: a Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study
This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Privacy Policy.
